M.D. - University of Sao Paulo Medical School ( 1994 - 1999)
General Surgery Residency - University of Sao Paulo Medical School (2000-2001)
Thoracic Surgery Residency - University of Sao Paulo Medical School (2002-2003)
Chief Resident of the Thoracic Surgery Division - University of Sao Paulo Medical School (2004)
Ph.D. - Thoracic Surgery Graduate Program, University of Sao Paulo Medical School (2005-2008)
MPH - Harvard University (2010 - 2012)
MBA - Imperial College London (2012-2014)
Staff Surgeon - Thoracic Surgery Division, University of Sao Paulo Medical School (2006 - 2013)
Chief of the Thoracic Surgery Divison at Sao Paulo State Cancer Institute - University of Sao Paulo Medical School (2009 - )
Assistant Professor of Thoracic Surgery - University of Sao Paulo Medical School (2013 - 2015)
Associate Professor of Thoracic Surgery - University of Sao Paulo Medical School (2015 - )
Scientific Director - Brazilian Society of Thoracic Surgery (2015 - 2021)

Suresh S. Ramalingam is the Executive Director of the Winship Cancer Institute of Emory University. He serves as Professor of Hematology and Medical Oncology and the Roberto C. Goizueta Chair for Cancer Research at the Emory University School of Medicine.

Dr. Ramalingam’s research is focused on the development of novel treatment approaches for patients with lung cancer. Specifically, his group has developed novel treatment options for lung cancer patients harboring an EGFR mutation, resulting in FDA approval of third generation inhibitors for metastatic NSCLC. He also leads clinical and translational investigations of novel immunotherapy approaches for the treatment of lung cancer. He has published more than 350 original manuscripts, review articles, editorials and book chapters. He serves as the principal investigator for the Emory University Lung Cancer SPORE award from the National Cancer Institute. He is also the contact principal investigator for the ECOG-ACRIN Thoracic Malignancies Translational Science Center Award from the National Cancer Institute.
Dr. Ramalingam serves as the Chair of the ECOG-ACRIN Thoracic Malignancies Committee and Deputy Chair for Therapeutics Programs at ECOG-ACRIN. He is the Editor-in-chief for ‘Cancer’ journal (American Cancer Society). Dr. Ramalingam is the recipient of several awards, including the James R. Eckman Award for Excellence at Emory University, and the Distinguished Cancer Scholar Award, Georgia Cancer Coalition. In addition, he is a recipient of the ASCO Career Development Award (2006–2009), the ECOG Young Investigator Award (2013), and the NCI ‘Clinical Investigators Team Leadership Award’ (2010-12). Dr. Ramalingam serves as a member of the board of directors for the International Association for the Study of Lung Cancer (IASLC) and as a member of the NCI Thoracic Malignancies Steering Committee. He is past president of the Georgia Society of Oncology and a former member of the Emory Healthcare board of directors.
Dr. Ramalingam received his medical degree at Kilpauk Medical College, Madras, India. He completed his residency in Internal Medicine at Wayne State University, Detroit, MI, where he also served as Chief Medical Resident. He then completed a fellowship in Hematology and Medical Oncology at the University of Pittsburgh Medical Center, Pittsburgh, PA.

Dr. Heather Wakelee is a Professor of Medicine and Chief of the Division of Oncology at Stanford University in California, USA and the Deputy Director of the Stanford Cancer Institute. She is a graduate of Princeton University and Johns Hopkins University School of Medicine and completed her post-graduate training at Stanford University. Dr. Wakelee is the President-Elect of the International Association for the Study of Lung Cancer (IASLC); Co-Chair of the Thoracic Committee, Executive Committee member, and Stanford Principal Investigator for the Eastern Cooperative Oncology Group (ECOG-ACRIN), and she is a Fellow of the American Society of Clinical Oncology (FASCO). Dr. Wakelee has authored or co-authored over 200 medical articles on lung cancer and thymic malignancies and is involved in dozens of clinical trials. Her research focuses on many specific lung cancer subtypes defined by specific mutations in EGFR, ALK, ROS1, RET, BRAF and others. Additionally she focuses on adjuvant therapy including immunotherapy and anti-angiogenesis agents and has active collaborations with colleagues focused in biomarkers and population science research. She is passionate about mentorship and is proud of the many former trainees who are now working in faculty positions as lung cancer investigators and care providers.